Vigil is the first cellular immunotherapy to demonstrate longer-term survival benefits in a randomized controlled trial of patients with solid tumors. The results of the company's Phase 2b study have ...

For more information on the Phase 1b clinical trial, visit: https://clinicaltrials.gov/study/NCT06732180 ...

Updated Phase 1 data for ELVN-001 expected mid-2025 as positive enrollment momentum continues Expected monotherapy and combination data from the ELVN-002 Phase 1 trials ...

CMS issued its Final Rule, establishing new Clinical Laboratory Improvement Amendments (CLIA) regulations (the Final ...

A stem cell therapy trial aimed at reducing neuroinflammation in patients with presymptomatic Alzheimer’s disease is underway ...

Recently announced positive data from pivotal randomized, placebo-controlled phase 3 clinical trial of CAN-2409 in intermediate-to-high risk, ...

Muscular Dystrophy Association Clinical & Scientific Conference, convening in Dallas, Texas, from March 16-18, will feature ...

We think it can be appropriate to present phase 2 trial participation as offering a small prospect of benefit,” researchers wrote. About 16% of patients enrolled in phase 2 cancer trials receive a ...

Natural products industry companies share overviews on the latest science on their branded ingredients and formulations to ...

The RNA inhibitor reduces levels of oxidized phospholipids, which are presumed to promote atherosclerosis, by more than 93%.

Proportion increases when considering off-label use but drops when considering drugs with substantial clinical benefit.

Completed enrollment of Phase 2 clinical trial of verekitug in patients with chronic rhinosinusitis with nasal polyps; top-line data expected ...